Tag:

Genentech

Latest Headlines

Latest Headlines

Syndax adds Genentech PD-L1 'atezo' combo pact to its growing pipeline

Genentech has agreed to lend its closely-watched checkpoint inhibitor atezolizumab to Syndax for a combo study with the Waltham, MA-based biotech's lead drug entinostat for triple-negative breast cancer, just three days after Syndax landed an $80 million crossover round.

Hunting fast OK in lung cancer, Roche racks up a positive PhII for 'atezo'

Roche is spotlighting another success for its PD-L1 checkpoint drug atezolizumab, with company execs applauding a positive finish in a big mid-stage study in non-small cell lung cancer. The news follows a string of steady pipeline advancements for a drug that has emerged as the pharma giant's biggest single late-stage blockbuster contender.

Genentech partners PD-L1 star 'atezo' with Immune Design activator

Just two days after striking a partnership with Merck, Immune Design has come back with another marquee pact. The West Coast biotech has inked a deal to partner its immune system activator CMB305 with Genentech's anti-PD-L1 star atezolizumab (MPDL3280A) in a Phase II study for soft tissue sarcoma.

Clovis pairs up with Roche on a high-profile immuno-oncology project

Clovis Oncology is planning to test whether its oral lung cancer drug can work in tandem with a closely watched injectable treatment from Roche's Genentech division, hoping to expand the potential for its breakthrough-designated therapy.

AC Immune snags milestone as Genentech picks Alzheimer's asset to advance to clinic

AC Immune has picked up a milestone payment in its CHF 400 million ($421 million) anti-tau collaboration with Genentech. The Roche subsidiary handed over the cash after selecting a tau-targeting antibody developed in the collaboration to advance toward the clinic.

FDA taps the brakes on Genentech's cobimetinib review

The FDA has opted to delay its review of cobimetinib in order to give regulators more time to consider additional Phase III data provided by Genentech.

Genentech's PD-L1 breakthrough star 'atezo' positioned to vault ahead on cancer

Behind the headlines here at ASCO, you'll find one of the biggest players in immuno-oncology quietly positioning itself to grab a leading role in the fast-emerging market.

UPDATED: Ex-Genentech dream team garners $217M to launch neurodegenerative player Denali

A group of high-profile ex-Genentech execs has rounded up a monster $217 million A round to launch Denali Therapeutics with plans to tackle neurodegenerative diseases like Alzheimer's disease, Parkinson's disease and ALS.

Tiny drugmakers top list of most profitable, but Shire and Gilead are there, too

Who are the most profitable companies in healthcare? Drug companies, with 7 out of 10 slots on a ranking by profit margin. Who are the most profitable drug companies? You might scratch your heads at all but a couple of names.

Genentech joins WaferGen's single cell analysis early-access program

Genentech has joined an early-access program for WaferGen Bio-systems' single cell sequencing technology. The alliance builds on proof-of-concept studies with the Broad Institute and BGI with a view to validating the use of the technology in industrial drug discovery.